Pathways of astragalus polysaccharide inhibiting angiotensin II-induced cardiac hypertrophy

doi:10.3969/j.issn.2095-4344.1255

Abstract

Abstract:

BACKGROUND: Astragalus polysaccharide, an important ingredient of astragalus, exerts pharmacological effects of anti-stress, anti-oxidation, anti-free radical and can reduce blood glucose.
OBJECTIVE: To explore the effect of astragalus polysaccharide on angiotensin II-induced cardiac hypertrophy and the underlying mechanism.
METHODS: H9c2 cardiomyocytes were provided by Experimental Center of Sun Yat-sen University, and then randomly divided into control group, angiotensin II (10-6 mol/L) group, angiotensin II (10-6 mol/L)+astragalus polysaccharide (10-6 mol/L) group, angiotensin II (10-6 mol/L) +astragalus polysaccharide (10-7 mol/L) group, and angiotensin II (10-6 mol/L)+astragalus polysaccharide (10-8 mol/L) group. The cells were cultured in the DMEM containing 10% fetal bovine serum for 48 hours. The surface area of cardiomyocytes, protein concentration, cell viability, and the mRNA expression of hypertrophy-related genes atrial natriuretic peptide and brain natriuretic peptide were detected to investigate the effect of astragalus polysaccharide on angiotensin II-induced cardiac hypertrophy.
RESULTS AND CONCLUSION: (1) Compared with the control group, angiotensin II significantly increased the surface area of H9c2 cardiomyocytes (P < 0.05). The cell area was significantly decreased after addition of astragalus polysaccharide compared with the control group, especially 10-6 mol/L astragalus polysaccharide (P < 0.05). (2) The total protein content and expression level of hypertrophy-related genes in the angiotensin II group were significantly higher than those in the control group. The total protein content and expression level of hypertrophy-related genes in the angiotensin II (10-6 mol/L)+astragalus polysaccharide (10-6 mol/L) and angiotensin II (10-6 mol/L)+astragalus polysaccharide (10-7 mol/L) groups were significantly down-regulated (P < 0.05). (3) Compared with the angiotensin II group, the survival rate of cardiomyocytes was increased significantly in the angiotensin II (10-6 mol/L)+astragalus polysaccharide (10-6 mol/L) and angiotensin II (10-6 mol/L)+astragalus polysaccharide (10-7 mol/L) groups (P < 0.05). (4) These results indicate that astragalus polysaccharide can effectively improve cardiac hypertrophy induced by angiotensin II.

中国组织工程研究杂志出版内容重点：组织构建；骨细胞；软骨细胞；细胞培养；成纤维细胞；血管内皮细胞；骨质疏松；组织工程

Key words: astragalus polysaccharides, cardiac hypertrophy, angiotensin II, nuclear factor-κB

CLC Number:

R496

Li Qin, Li Yan, Gao Shanshan, Zheng Jintao. Pathways of astragalus polysaccharide inhibiting angiotensin II-induced cardiac hypertrophy[J]. Chinese Journal of Tissue Engineering Research, 2019, 23(19): 3086-3091.

Figures/Tables 1

References

[1] 马丽媛,吴亚哲,王文陈,等.《中国心血管病报告2017》要点解读[J].中国心血管杂志，2018,23(1):3-6.

[2] Hirota H,Chen J,Betz U A K,et al.Loss of a gp130 cardiac muscle cell survival pathway is a critical event in the onset of heart failure during biomechanical stress.Cell.1999;97(2): 189-198.[3] 许志威,吴伟康.心肌肥大?凋亡?纤维化?——高血压心肌肥厚中心肌重塑机制[J].中山大学研究生学刊,2005,26(1):9-20.

[4] Molkentin JD, Lu JR, Antos CL,et al.A calcineurin-dependent transcriptional pathway for cardiac hypertrophy.Cell. 1998; 93(2):215-228.

[5] Shah BH, Catt KJ.A central role of EGF receptor transactivation in angiotensin II-induced cardiac hypertrophy. Trends Pharmacol Sci. 2003;24(5):239-244.

[6] 符民桂,唐朝枢.心肌肥大的细胞信号转导机制[J].基础医学与临床,2000,20(3):1-4+9-96.

[7] Lyon RC, Zanella F, Omens JH,et al .Mechanotransduction in Cardiac Hypertrophy and Failure. Circ Res. 2015;116(8): 1462-1476.

[8] 魏巍,付守廷,李少杰.血管紧张素Ⅱ致心肌肥大及机制[J].中南药学,2005,3(1):41-42.

[9] Pei JF, Yan YF, Tang X,et al.Human paraoxonase gene cluster overexpression alleviates angiotensin II-induced cardiac hypertrophy in mice. Sci China Life Sci. 2016;59(11): 1115-1122.

[10] Fujishima Y, Maeda N, Matsuda K, et al.Effect of adiponectin on cardiac β-catenin signaling pathway under angiotensin II infusion. Biochem Biophys Res Commun. 2014;444(2): 224-229.

[11] 赵素玲,王洪新,周振华,等.黄芪多糖对异丙肾上腺素诱导的乳大鼠心肌细胞肥大的保护作用[J].中国药理学通报, 2011,27(12): 1682-1686.

[12] 姚红旗,侯雅竹,王贤良,等.黄芪心血管药理作用研究进展[J].河南中医,2019，38(2):302-306.

[13] 张瓅方,高丽,李超,等.黄芪丹参配伍提取物对大鼠心肌梗死后心室重构的影响[J].科学技术与工程,2018,18(30):145-149.

[14] 孙敏,吴国泰,杜丽东,等.黄芪在心血管系统方面的药理活性研究进展[J].甘肃中医药大学学报,2018,35(5):91-94.

[15] 范宗静,谢连娣,崔杰,等.黄芪多糖后处理通过抑制线粒体损伤介导的凋亡保护心肌缺血再灌注损伤[J].辽宁中医杂志, 2018, 45(7):1357-1360.

[16] 秦琦,李文杰,杨莺,等.中药对大鼠心肌细胞凋亡影响的Meta分析[J].中西医结合心脑血管病杂志,2018,16(19):2766-2773.

[17] 梁灵君,王洪新,孙雪芳,等. Toll 样受体 4/NF-κB 信号通路参与黄芪多糖对肿瘤坏死因子α诱导的乳大鼠心肌细胞肥大的抑制作用[J].中国药理学与毒理学杂志,2013,27(2):44-49.

[18] Luan A,Tang F,Yang Y,et al.Astragalus polysaccharide attenuates isoproterenol-induced cardiac hypertrophy by regulating TNF-α/PGC-1α signaling mediated energy biosynthesis. Environ Toxicol Pharmacol. 2015 ;39(3): 1081-1090.

[19] 芦新,杨波.黄芪多糖对心肌细胞缺氧复氧过程中细胞损伤、线粒体途径凋亡的影响[J].海南医学院学报, 2017,23(24): 3338-3341.

[20] Harvey PA, Leinwand LA. The cell biology of disease: Cellular mechanisms of cardiomyopathy. J Cell Biol. 2011;194(3): 355-365.

[21] Marian AJ,Roberts R. The molecular genetic basis for hypertrophic cardiomyopathy. J Mol Cell Cardiol. 2001;33(4): 655-670.

[22] Zhou N, Li L, Wu J, et al.Mechanical stress-evoked but angiotensin II-independent activation of angiotensin II type 1 receptor induces cardiac hypertrophy through calcineurin pathway. Biochem Biophys Res Commun. 2010;397(2): 263-269.

[23] Fu J, Wang Z, Huang L, et al.Review of the botanical characteristics, phytochemistry, and pharmacology of Astragalus membranaceus (Huangqi). Phytother Res. 2014; 28(9):1275-1283.

[24] 薛善乐,严智慧,杨珊莉,等.基于证候积分——黄芪剂量关系应用补阳还五汤治疗缺血性卒中临床观察[J/OL].中医药临床杂志, 2019，31(1):123-126.

[25] 闵清,白育婷,余薇,等.黄芪多糖对乳鼠心肌细胞缺氧/复氧损伤的保护作用[J].中国药理学通报, 2010, 26(12):1661-1664.

[26] 郑敏,杨宏杰,张丹,等.黄芪提取液清除自由基的实验研究[J].山东中医志,2004,23(12):743-745.

[27] Baldwin Jr AS. The NF-κB and IκB proteins: new discoveries and insights. Annu Rev Immunol. 1996;14:649-681.

[28] 刘怡雯.核因子κB与肥厚性心肌病关系的研究进展[J].中国分子心脏病学杂志,2004,1(4):48-51.

[29] 王丹阳,朱广瑾,徐成丽.NF-κB 在某些心血管疾病中的作用[J].基础医学与临床,2011,31(9):1070-1073.

[30] Hall G,Hasday JD,Rogers TB.Regulating the regulator: NF-κB signaling in heart. J Mol Cell Cardiol. 2006;41(4):580-591.

[31] Ogata T,Miyauchi T,Sakai S,et al.Myocardial fibrosis and diastolic dysfunction in deoxycorticosterone acetate-salt hypertensive rats is ameliorated by the peroxisome proliferator-activated receptor-alpha activator fenofibrate, partly by suppressing inflammatory responses associated with the nuclear factor-kappa-B pathway. J Am Coll Cardiol. 2004;43(8):1481-1488.